• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人前列腺特异性抗原γ-精浆蛋白的类胰凝乳蛋白酶活性

The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein.

作者信息

Akiyama K, Nakamura T, Iwanaga S, Hara M

机构信息

Department of Legal Medicine, Kurume University School of Medicine, Fukuoka, Japan.

出版信息

FEBS Lett. 1987 Dec 10;225(1-2):168-72. doi: 10.1016/0014-5793(87)81151-1.

DOI:10.1016/0014-5793(87)81151-1
PMID:3691800
Abstract

gamma-Seminoprotein (gamma-Sm) is a human prostate-specific antigen and a serine protease judging from the complete amino acid sequence which shows extensive homology with the kallikrein family. The enzymatic activity of gamma-Sm was defined as a chymotrypsin-like activity using reduced and S-3-(trimethylated amino)propylated lysozyme and insulin-oxidized A and B chains as substrates. The -Leu/Ser- peptide bond of lysozyme was rapidly hydrolyzed by gamma-Sm. gamma-Sm also hydrolyzed the -Phe/Glu- of lysozyme and the -Leu/Cys(SO3H)- of insulin B chain. Insulin A chain and arginyl- or lysyl-linkage of these proteins were not hydrolyzed by gamma-Sm at all.

摘要

γ-精蛋白(γ-Sm)是一种人前列腺特异性抗原,从其完整氨基酸序列判断它是一种丝氨酸蛋白酶,该序列与激肽释放酶家族具有广泛的同源性。使用还原型和S-3-(三甲基化氨基)丙基化溶菌酶以及胰岛素氧化的A链和B链作为底物,γ-Sm的酶活性被定义为类似胰凝乳蛋白酶的活性。溶菌酶的-Leu/Ser-肽键被γ-Sm迅速水解。γ-Sm还能水解溶菌酶的-Phe/Glu-以及胰岛素B链的-Leu/Cys(SO3H)-。γ-Sm根本不会水解这些蛋白质的胰岛素A链以及精氨酰或赖氨酰连接键。

相似文献

1
The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein.人前列腺特异性抗原γ-精浆蛋白的类胰凝乳蛋白酶活性
FEBS Lett. 1987 Dec 10;225(1-2):168-72. doi: 10.1016/0014-5793(87)81151-1.
2
[On the chymotrypsin-like activity of prostate specific antigen, gamma-seminoprotein (gamma-Sm)--forensic immunological studies of body fluids and secretions, Report XXXV].[关于前列腺特异性抗原γ-精蛋白(γ-Sm)的胰凝乳蛋白酶样活性——体液和分泌物的法医免疫学研究,报告XXXV]
Nihon Hoigaku Zasshi. 1988 Apr;42(2):154-60.
3
Two prostate-specific antigens, gamma-seminoprotein and beta-microseminoprotein.
J Lab Clin Med. 1989 May;113(5):541-8.
4
Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma.人精浆糖蛋白γ-精蛋白的分离、特性鉴定及氨基酸序列分析
Eur J Biochem. 1987 Dec 30;170(1-2):111-20. doi: 10.1111/j.1432-1033.1987.tb13674.x.
5
[Analysis of antigens recognized by anti-gamma-seminoprotein antibody and anti-prostate-specific antigen antibody by means of Ouchterlony method and western blotting method].[采用免疫双扩散法和蛋白质印迹法分析抗γ-精蛋白抗体和抗前列腺特异性抗原抗体识别的抗原]
Nihon Hinyokika Gakkai Zasshi. 1989 Mar;80(3):349-52. doi: 10.5980/jpnjurol1989.80.349.
6
[Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].[用于监测前列腺癌患者的肿瘤标志物的临床研究;前列腺特异性抗原的评估以及与前列腺酸性磷酸酶和γ-精浆蛋白的比较]
Nihon Gan Chiryo Gakkai Shi. 1990 Nov 20;25(11):2627-39.
7
[Studies on prostate specific antigen, gamma-seminoprotein (gamma-Sm) as a tumor marker of prostatic cancer].
Rinsho Byori. 1984 Jul;32(7):781-5.
8
[Prostatic acid phosphatase (PAP), gamma-seminoprotein (gamma-Sm) and prostate specific antigen (PA) in prostatic cancer].[前列腺癌中的前列腺酸性磷酸酶(PAP)、γ-精浆蛋白(γ-Sm)和前列腺特异性抗原(PA)]
Hinyokika Kiyo. 1988 Aug;34(8):1389-96.
9
Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I.前列腺特异性抗原对其主要生理底物——精子活力抑制因子前体/精液凝胶蛋白I的蛋白水解活性的表征
Biochemistry. 1997 Apr 1;36(13):3811-9. doi: 10.1021/bi9626158.
10
[Clinical evaluation of prostate-specific antigens (gamma-seminoprotein: gamma-Sm)--gamma-seminoprotein in serum measured by gamma-Sm monoclonal antibodies].[前列腺特异性抗原(γ-精浆蛋白:γ-Sm)的临床评估——用γ-Sm单克隆抗体检测血清中的γ-精浆蛋白]
Nihon Hinyokika Gakkai Zasshi. 1985 Feb;76(2):165-73. doi: 10.5980/jpnjurol1928.76.2_165.

引用本文的文献

1
The Potentiality of Prostate-Specific Antigen as a Prognostic Biomarker in Breast Cancer.前列腺特异性抗原作为乳腺癌预后生物标志物的潜力
Cureus. 2023 Sep 3;15(9):e44621. doi: 10.7759/cureus.44621. eCollection 2023 Sep.
2
Heparin Blocks the Inhibition of Tissue Kallikrein 1 by Kallistatin through Electrostatic Repulsion.肝素通过静电排斥作用阻止激肽释放酶抑制因子 1 对组织激肽释放酶的抑制。
Biomolecules. 2020 May 28;10(6):828. doi: 10.3390/biom10060828.
3
Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.
前列腺特异性抗原激活的二硫代氨基甲酸酯前药靶向前列腺癌。
Bioorg Med Chem Lett. 2020 Jun 1;30(11):127148. doi: 10.1016/j.bmcl.2020.127148. Epub 2020 Mar 28.
4
Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility.前列腺特异性抗原(PSA/KLK3)的突变与男性不育有关。
Sci Rep. 2017 Sep 11;7(1):11225. doi: 10.1038/s41598-017-10866-1.
5
Towards engineering hormone-binding globulins as drug delivery agents.致力于将激素结合球蛋白工程化为药物递送剂。
PLoS One. 2014 Nov 26;9(11):e113402. doi: 10.1371/journal.pone.0113402. eCollection 2014.
6
Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen.一种由前列腺特异性抗原裂解的阿霉素白蛋白结合前药的优化。
ACS Med Chem Lett. 2010 May 26;1(5):234-8. doi: 10.1021/ml100060m. eCollection 2010 Aug 12.
7
Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.靶向前列腺特异性抗原的重组新城疫病毒用于前列腺癌的病毒治疗。
J Virol. 2013 Apr;87(7):3792-800. doi: 10.1128/JVI.02394-12. Epub 2013 Jan 23.
8
Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.商业上可获得的从人精液中纯化的 PSA 中胰蛋白酶样蛋白水解污染。
Prostate. 2012 Aug 1;72(11):1233-8. doi: 10.1002/pros.22474. Epub 2011 Dec 28.
9
Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis.血栓形成轴蛋白酶对人激肽释放酶相关肽酶的激活谱
Protein Sci. 2008 Nov;17(11):1998-2007. doi: 10.1110/ps.036715.108. Epub 2008 Aug 12.
10
Twenty Years of PSA: From Prostate Antigen to Tumor Marker.前列腺特异性抗原的二十年:从前列腺抗原到肿瘤标志物
Rev Urol. 2007 Summer;9(3):113-23.